Some Title

Lorenzo Fabbri1,2,✉, and Martine Vrijheid1,2

1 Barcelona Institute for Global Health (ISGlobal), Barcelona, Spain  
2 Pompeu Fabra University, Barcelona, Spain

✉ Correspondence: [Lorenzo Fabbri <lorenzo.fabbri@isglobal.org>](mailto:lorenzo.fabbri@isglobal.org)

# Abstract

**Background**

**Objectives**

**Methods**

**Results**

**Discussion**

* The title should be less or equal than 300 characters. It should indicate the study design, the subject of the paper, information regarding exposures and outcomes assessed, and whether the study was observational or experimental.
* The suggested length of the abstract is less or equal than 300 words.
* The suggested length is <7,000 words, excluding abstract, references, tables, figure captions, acknowledgments, and Supplementary Material.
  + Concise sub-headings should be less or equal than 8 words, and they should be used to organize information rather than summarize the results.
  + In-text citations with superscript numbers: outside periods and commas, but inside colons and semicolons.

# Introduction

## Background and rationale

* Brief review of the literature to summarize current knowledge.
  + Acknowledge inconsistencies.
  + For each study, indicate whether it was observational or experimental, and note key characteristics of study populations or experimental models.
* Explain the scientific background and rationale for the investigation being reported.
  + Identify knowledge gaps addressed by the current study.
* Provide context for the study: include information on exposures and outcomes, and why they are relevant to environmental health.

## Objectives

* Provide a clear description of the study hypotheses/aims/objectives, and eventually an overview of the approach used to address them.

# Methods

## Study design

* Present key elements of study design

## Setting

* Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection.

## Participants

* Cohort study: eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up.
* Cross-sectional study: give eligibility criteria, and the sources and methods of selection of participants.
* Describe informed consent protocols.
* Report how and by whom *race* or *ethnicity* was defined, and why this information was included in the study design. Disaggregate race and ethnicity data to the fullest extent possible.

## Variables

* Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers.
* Explain the rationale for treating race as an exposure, confounder, effect modifier, or other type of variable in analyses.

### Confounders

### Endocrine disrupting chemicals

### Corticosteroids

### Neurodevelopment

## Data sources and measurement

* For each variable of interest, give sources of data and details of methods of assessment (measurement).

## Bias

* Describe any efforts to address potential sources of bias.

## Study size

* Explain how the study size was arrived at.

## Quantitative variables

* Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why.

## Statistical methods

* Methods for selecting potential confounders (provide DAGs).
* Describe all statistical methods with assumptions, including those used to control for confounding.
  + Description of outcome model, weighting method, estimand, and balance assessment.
  + Description of method used to estimate effects (e.g., g-computation).
  + Description of method used for SE and CI.
* Describe any methods used to examine subgroups and interactions (sub-group analysis or moderation analysis or analysis of effect-modification).
* Explain how missing data were addressed.
* Cohort study: explain how loss to follow-up was addressed.
* Cross-sectional study: describe analytical methods taking account of sampling strategy.
* Describe any sensitivity analyses.
* When referring to previous publications for methods’ details, include a brief description of the approach, key assumptions and limitations, and any deviation.
* Names and version numbers for the used software packages, including non-data arguments if deviating from the default ones.

# Results

## Participants

* Give reasons for non-participation at each stage.

## Descriptive data

[Table 1](#tbl-chem-info)

## Outcome data

## Main results

* All results on which study conclusions or inferences are based, including null findings and results of secondary or sensitivity analyses, must be reported. Use of sub-headings that describe the nature of the results (but no declarative statements).
  + Provide a clear and concise description of all findings without extrapolating beyond the study results.
  + Do not limit results to those *statistically significant* or that support the study hypotheses. Avoid using statistical significance testing as the sole or primary criterion for interpreting the obtained results. If significance testing or *p*-values are used, report numeric *p*-values, rounded to 1-2 digits, for all results.
* Give unadjusted and confounder-adjusted estimates and their precision (e.g., confidence interval). Make clear which confounders were adjusted for and why they were included. Include the number of observations for each analysis after accounting for missing data. Include numeric data within figures (e.g., forest plots), or provide tables with corresponding numeric data for all figures.
  + [marginaleffects tables](https://vincentarelbundock.github.io/marginaleffects/articles/tables.html).
* Report category boundaries when continuous variables were categorized.

## Other analyses

* Report other analyses done (e.g., analyses of subgroups and interactions, and sensitivity analyses).

# Discussion

## Key results

* Summarise key results with reference to study objectives.
* Provide a review of the relevant literature to put the study findings into context.
  + It should be complete and balanced, including inconsistent results.
  + It should include, for each source, sufficient details: study design, sample size, population, specific exposures and outcomes.

## Limitations

* Discuss limitations of the study, taking into account sources of potential bias or imprecision.
* Discuss both direction and magnitude of any potential bias.

Some limitations:

* Cross-sectional study.
* Chemicals measured in night and morning samples, whereas metabolites (the outcome) were measured only in night samples.
* Cortisol measured at night, when should be lowest.
* Change of estimand when trimming weights.
* Model misspecification.
* Mixtures effect.
* Residual confounding.
* Some confounders were not used since large percentage of missing values.
* Multiple comparisons.

## Interpretation

* End with a summary of the key findings and their implications for the study hypotheses, future research, and policy.
* Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence.

## Generalisability

* Discuss the generalisability (external validity) of the study results.

# Funding

* Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based.

# References

# Tables

* Begin each table on a new page after the list of references.
* Tables may not contain parts.
* Provide the title for each table above the table and the notes below the table.
* List footnotes after the general one, one per line and indicated with a lowercase italicized letter.

# Descriptive data

## Study populations

* Basic characteristics of study participants (demographic, clinical, social), by cohort and overall.
  + Include all covariates included in primary or secondary analyses.
  + Indicate number of participants with missing data for each variable of interest.
  + Report numbers of outcome events or summary measures.

## Endocrine disruptors

* Levels of unprocessed biomarkers (chemicals), with IDs.
* Report: minimum and maximum, percentiles, and number of observations above/below the assay’s LOD and LOQ.

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Table 1: Information about the non-persistent EDCs.   | Compound | Symbol | PubChem CID | CTD ID | Exposome Explore ID | Parental compound | | --- | --- | --- | --- | --- | --- | | OP pesticide metabolites |  |  |  |  |  | | diethyl dithiophosphate | DEDTP | 9274 | C000654497 | NA | NA | | diethyl phosphate | DEP | 654 | C034789 | NA | NA | | diethyl thiophosphate | DETP | 3683036 | C035638 | NA | NA | | dimethyl dithiophosphate | DMDTP | NA | Unsure | NA | NA | | dimethyl phosphate | DMP | 13134 | C007477 | NA | NA | | dimethyl thiophosphate | DMTP | 168140 | C040340 | NA | NA | | Phenols |  |  |  |  |  | | bisphenol A | BPA | 6623 | C006780 | 1418 | NA | | ethyl-paraben | ETPA | 8434 | C012313 | 1422 | NA | | methyl-paraben | MEPA | 7456 | C015358 | 1421 | NA | | n‑butyl‑paraben | BUPA | 7184 | C038091 | 1424 | NA | | oxybenzone | OXBE | 4632 | C005290 | 1419 | NA | | propyl-paraben | PRPA | 7175 | C006068 | 1423 | NA | | triclosan | TRCS | 5564 | D014260 | 1420 | NA | | Phthalate metabolites |  |  |  |  |  | | mono benzyl phthalate | MBzP | 31736 | C103325 | 1397 | BzBP | | mono‑2‑ethyl 5‑carboxypentyl phthalate | MECPP | 148386 | C051450 | 1403 | DEHP | | mono‑2‑ethyl‑5‑hydroxyhexyl phthalate | MEHHP | 170295 | C479069 | 1402 | DEHP | | mono‑2‑ethyl‑5‑oxohexyl phthalate | MEOHP | 119096 | C080276 | 1401 | DEHP | | mono‑2‑ethylhexyl phthalate | MEHP | 21924291 | C016599 | Unsure | DEHP | | mono‑4‑methyl‑7‑hydroxyoctyl phthalate | oh-MiNP | 102401880 | NA | 1451 | NA | | mono‑4‑methyl‑7‑oxooctyl phthalate | oxo-MiNP | 102401881 | NA | 1492 | NA | | mono‑iso‑butyl phthalate | MiBP | 92272 | C575690 | 1399 | DiBP | | mono‑n‑butyl phthalate | MnBP | 8575 | C028577 | 1398 | NA | | monoethyl phthalate | MEP | 75318 | C581825 | 1396 | DEP | |

## Corticosteroids

* Levels of unprocessed biomarkers (metabolites), with IDs.
* Table comparing subjects with and without measurement of steroids.

# Main results

* RQ2: group chemicals by class, and for each chemical report results with metabolites (avg\_comparisons with estimate, SE, s-value, CI).
* RQ3: report results with outcome (avg\_comparisons with estimate, SE, s-value, CI).

# Other analyses